Share this article
Share this article
AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ A physician with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David s Medical Center is among the first in the world to participate in a clinical trial to evaluate the safety and efficacy of a new cardiac-specific catheter used during pulsed field ablation (PFA), a new approach to treating patients with atrial fibrillation (A Fib). Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, recently participated in the first-in-human trials of this catheter in Europe.
Share this article
Share this article
AUSTIN, Texas, Feb. 5, 2021 /PRNewswire/ Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David s Medical Center are among the first in the world to participate in a clinical trial to evaluate a new esophageal protection device designed to make ablation procedures safer for patients with atrial fibrillation (A Fib), the most common type of cardiac arrhythmia. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., cardiac electrophysiologist at TCAI, recently participated in the first-in-human trials in Europe.
Abbott Laboratories (NYSE:ABT), (BSGM) - BioSig Technologies Achieves First Commercial Sale Of Its PURE EP System benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.